Patents by Inventor Frederic Bushman

Frederic Bushman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods Comprising a Defined Microbiome and Methods of Use Thereof
    Publication number: 20210093681
    Abstract: The invention features the use of a defined microbial consortia for the replacement of a gut microbiome associated with disease. In particular, the invention provides for the treatment of hyperammonemia, Clostridium difficile colitis, hepatic encephalopathy associated with cirrhosis, and inflammatory bowel disease.
    Type: Application
    Filed: November 23, 2020
    Publication date: April 1, 2021
    Inventors: Frederic Bushman, Gary Wu, James Lewis, Mark Goulian
  • Compositions comprising a defined microbiome and methods of use thereof
    Patent number: 10842832
    Abstract: The invention features the use of a defined microbial consortia for the replacement of a gut microbiome associated with disease. In particular, the invention provides for the treatment of hyperammonemia, Clostridium difficile colitis, hepatic encephalopathy associated with cirrhosis, and inflammatory bowel disease.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: November 24, 2020
    Assignee: The Trustees of The University Of Pennsylvania
    Inventors: Frederic Bushman, Gary Wu, James Lewis, Mark Goulian
  • COMPOSITIONS COMPRISING A DEFINED MICROBIOME AND METHODS OF USE THEREOF
    Publication number: 20190105359
    Abstract: The invention features the use of a defined microbial consortia for the replacement of a gut microbiome associated with disease. In particular, the invention provides for the treatment of hyperammonemia, Clostridium difficile colitis, hepatic encephalopathy associated with cirrhosis, and inflammatory bowel disease.
    Type: Application
    Filed: August 28, 2018
    Publication date: April 11, 2019
    Inventors: Frederic Bushman, Gary Wu, James Lewis, Mark Goulian
  • Compositions and methods comprising a defined microbiome and methods of use thereof
    Patent number: 10058576
    Abstract: The invention features the use of a defined microbial consortia for the replacement of a gut microbiome associated with disease. In particular, the invention provides for the treatment of hyperammonemia, Clostridium difficile colitis, hepatic encephalopathy associated with cirrhosis, and inflammatory bowel disease.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: August 28, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Frederic Bushman, Gary Wu, James Lewis, Mark Goulian
  • COMPOSITIONS AND METHODS COMPRISING A DEFINED MICROBIOME AND METHODS OF USE THEREOF
    Publication number: 20160243175
    Abstract: The invention features the use of a defined microbial consortia for the replacement of a gut microbiome associated with disease. In particular, the invention provides for the treatment of hyperammonemia, Clostridium difficile colitis, hepatic encephalopathy associated with cirrhosis, and inflammatory bowel disease.
    Type: Application
    Filed: April 4, 2016
    Publication date: August 25, 2016
    Inventors: Frederic Bushman, Gary Wu, James Lewis, Mark Goulian
  • Methods and compositions for retroviral preintegration complex-based assays
    Publication number: 20060134612
    Abstract: Disclosed are solution-based methods of screening for molecules that modulate the integration of retroviral cDNA into target DNA molecules. These methods can be used to identify molecules that modulate (e.g., inhibit) the integration of unintegrated retroviral cDNA. Such PIC activity modulators may have therapeutic application, for example, to treat or prevent diseases caused by or associated with retroviral infection.
    Type: Application
    Filed: February 9, 2005
    Publication date: June 22, 2006
    Inventors: Frederic Bushman, Julie Mullin
  • Intergrase assay
    Patent number: 6727058
    Abstract: The present invention provides packaging cell lines and recombinant lentiviral or retroviral particles produced therefrom, particularly pseudotyped retroviral particles. The packaging cell lines of the invention are produced by inducibly expressing an envelope protein by methods described herein. Also described is a screening assay for compounds that affect integration of viral nucleic acid into target (e.g., host) nucleic acid. Such compounds are identified based on their effect on viral integrase.
    Type: Grant
    Filed: March 12, 2001
    Date of Patent: April 27, 2004
    Assignee: The Salk Institute for Biological Studies
    Inventors: Frederic Bushman, Mark Hansen
  • Method of identifying inhibitors of topoisomerase DNA religation
    Patent number: 6620588
    Abstract: The present invention provides methods for screening compounds capable of modulating nucleic acid-modifying enzymatic activity, including topoisomerase activity.
    Type: Grant
    Filed: May 31, 2000
    Date of Patent: September 16, 2003
    Assignee: Salk Institute for Biological Studies
    Inventors: Frederic Bushman, Young Hwang
  • Retroviral packaging cell line
    Publication number: 20010009772
    Abstract: The present invention provides packaging cell lines and recombinant lentiviral or retroviral particles produced therefrom, particularly pseudotyped retroviral particles. The packaging cell lines of the invention are produced by inducibly expressing an envelope protein by methods described herein. Also described is a screening assay for compounds that affect integration of viral nucleic acid into target (e.g., host) nucleic acid. Such compounds are identified based on their effect on viral integrase.
    Type: Application
    Filed: March 12, 2001
    Publication date: July 26, 2001
    Inventors: Inder M. Verma, Tal Kafri, Frederic Bushman, Mark Hansen
  • Retroviral packaging cell line
    Patent number: 6218181
    Abstract: The present invention provides packaging cell lines and recombinant lentiviral or retroviral particles produced therefrom, particularly pseudotyped retroviral particles. The packaging cell lines of the invention are produced by inducibly expressing an envelope protein by methods described herein. Also described is a screening assay for compounds that affect integration of viral nucleic acid into target (e.g., host) nucleic acid. Such compounds are identified based on their effect on viral integrase.
    Type: Grant
    Filed: September 3, 1998
    Date of Patent: April 17, 2001
    Assignee: The Salk Institute for Biological Studies
    Inventors: Inder M. Verma, Tal Kafri, Frederic Bushman, Mark Hansen